5AM Venture Management LLC Acquires 77,500 Shares of Surrozen, Inc. $SRZN

5AM Venture Management LLC raised its position in shares of Surrozen, Inc. (NASDAQ:SRZN) by 25.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 387,500 shares of the company’s stock after purchasing an additional 77,500 shares during the quarter. Surrozen accounts for approximately 2.8% of 5AM Venture Management LLC’s holdings, making the stock its 14th biggest position. 5AM Venture Management LLC’s holdings in Surrozen were worth $8,758,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Empery Asset Management LP bought a new stake in shares of Surrozen during the 4th quarter valued at about $2,350,000. Spruce Street Capital LP bought a new stake in shares of Surrozen during the 4th quarter valued at about $9,764,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Surrozen by 50.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. State Street Corp grew its stake in shares of Surrozen by 82.5% during the 4th quarter. State Street Corp now owns 24,326 shares of the company’s stock valued at $550,000 after purchasing an additional 11,000 shares during the period. Finally, Armistice Capital LLC bought a new stake in shares of Surrozen during the 2nd quarter valued at about $536,000. 66.57% of the stock is currently owned by institutional investors.

Surrozen Trading Up 5.7%

Shares of NASDAQ:SRZN opened at $24.04 on Thursday. The stock has a 50 day moving average of $27.65 and a 200 day moving average of $24.85. The company has a market cap of $279.10 million, a PE ratio of -0.64 and a beta of 0.51. Surrozen, Inc. has a 12-month low of $8.00 and a 12-month high of $35.00.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The company had revenue of $5.00 million for the quarter, compared to the consensus estimate of $4.00 million. Surrozen had a negative net margin of 4,810.50% and a negative return on equity of 4,055.04%. Equities research analysts predict that Surrozen, Inc. will post -7.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Charles O. Williams sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $67,859.88. Following the transaction, the chief operating officer directly owned 16,571 shares of the company’s stock, valued at approximately $552,311.43. The trade was a 10.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Craig C. Parker sold 4,524 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $150,784.92. Following the completion of the transaction, the chief executive officer directly owned 16,553 shares in the company, valued at approximately $551,711.49. This represents a 21.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,144 shares of company stock valued at $271,440 in the last 90 days. 31.74% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a research note on Tuesday, March 24th. TD Cowen assumed coverage on Surrozen in a research note on Tuesday, April 21st. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $44.00 price objective (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.